Bangkok (VNA) - Thailand has produced its first locally developed targeted therapy pill for cancer treatment - Imcranib 100. This is the result of the scientic vision and leadership of Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana.
Targeted therapy is a modern cancer treatment approach that focuses on attacking specific cancer cells while sparing healthy cells, thereby reducing side effects commonly associated with traditional treatments such as chemotherapy, according to a statement from the Chulabhorn Royal Academy (CRA).
This method also allows for more personalised treatment plans tailored to each patient’s condition,” it said.
Driven by concern for cancer patients with limited access to effective medicines, Princess Chulabhorn established a pharmaceutical manufacturing facility under royal initiative at Phimanmas Residence in Sattahip district of Chon Buri in 2020. The plant, operating under the CRA, is Thailand’s first cancer drug manufacturing site certified to international GMDP PIC/s standards. It was created to ensure domestic production capacity from research to industrial scale, aiming to reduce reliance on costly drug imports and strengthen national pharmaceutical expertise.
Treatment using Imcranib 100 is now available at Chulabhorn Hospital, signicantly reducing treatment costs and increasing access to care for Thai patients, according to the CRA.
Additionally, the Chulabhorn Research Institute has successfully developed Thailand’s first targeted biological drug, Trastuzumab (registered as Herdara), also approved by the FDA on May 20. Developed entirely by Thai researchers without foreign technology transfer, Herdara represents a major milestone in biopharmaceutical self-reliance./.
